• |
Complete service from target valiadation, |
 |
|
assay development and compound screening |
• |
MOA study, drug combination study, |
|
compound resistance identification and |
|
charaterizaiton |
• |
Genotyping and phenotyping of patient |
|
support clinical virology |
|
|
|
|
|
A series of in vitro assays are available for HCV, HBV, Influenza virus, RSV, and Herpes |
virus (HSV-1, HSV-2, HCMV) to support client Hit ID and Lead discovery effort. |
|
Anti-HCV Assay and Screening |
|
HCV replicon assays (GT1a, 1b or 2a) are available in both 96-well and 384-well format. The infectious system based on GT2a JFH-1, with or without reporter gene, is for compound screening to capture full cycle of HCV replication. HDB also provides customized replicon |
construction service for other genotypes with screening supports. |
- |
|
Evaluation of effect of drug combination against HCV |
- |
Generation of drug resistant HCV mutants by cell culture passaging or site-directed mutagenesis |
- |
Drug resistant mutation identification and profiling |
- |
Genotyping and phenotyping of viral genes (NS3/NS5A/NS5B) derived from HCV patients |
|
|
 |
BMS790052 profiling against HCV 2a F28S/Y or Y93H/N mutant replicons |
|
 |
Synergistic effect of two HCV compounds (Figure generated by Macsynergy II) |
|
Anti-HBV Assay and Screening |
|
A primary 96-well/384-well viral DNA qPCR or HBsAg ELISA assay is available in HDB to screen compound inhibiting HBV replication or HBsAg secretion in HepG2.2.15 cell line. Other GT (B/C/D) HBV-expressing cell lines are available for compound screening. HBV infectious system (HepG2-hNTCP or primary human hepatocyte) is also available for |
compound efficacy test. |
- |
|
Evaluation of drug combination effect against HBV |
- |
Compound profiling against drug resistant HBV mutants |
- |
Cytokine stimulation compound screening in PBMC by cytokine multiplexed assay or function assay |
|
|
 |
|
HBV compound in combination of TDF or ETV with different drug ratio: combination with TDF shows |
|
slight synergism, combination with ETV shows significant synergism (Figure generated by CompuSyn) |
|
 |
Multiple cytokine quantification by multiplex assay |
|
Virus CPE Assay for Compound Screening |
|
CPE assay (96-well/384-well) is available at HDB for testing compound inhibition of several viruses, including influenza virus A/B, RSV (Respiratory Syncytial Virus), Herpes virus (HSV-1, HSV-2), Enterovirus (EV71 and Coxsackie Virus). Plaque assay is also |
available for compound efficacy test. |
|
 |
Influenza virus CPE Assay |
|
 |
HSV-1 plaque reduction assay |
|
Other Services |
|
- |
|
Compound profiling against different influenza virus strains |
- |
Assay development for mechanism of action of lead compounds |
- |
Cytotoxicity evaluation of the tested compounds |
|
|
 |
Tet-inducible HBV-expressing cell line |
|
Contributions to Clients’ Publications |
|
1. |
|
Pickford C., etc: Use of Clinical Samples to Study the Emergence of Resistance to Filibuvir (PF -00868554) and the Potential to Combine with NS5A Inhibitors, Presented at the American Association for the Study of Liver Diseases (AASLD), October 29- |
|
November 2, 2010, Boston, USA |
2. |
Troke, P., etc: Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected Patients, Antimicrobial Agents and Chemotherapy |
|
|
3. |
Christ F., etc, Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization, Antimicrobial Agents |
|
|
|
|
|
|
|
Related Services |
|
|
|
沪公网安备 31011502003320号